We have evaluated three commercial assays for collagen cross-links, two urine assays and a recently developed serum assay, as markers of bone turnover in 30 postmenopausal women with osteoporosis during their first year of treatment with the anti-resorptive drug alendronate.
Before treatment, urine free deoxypyridinoline crosslinks (Dpd), urine N-telopeptide crosslinks (NTx) and serum C-telopeptide (CTx) values were within postmenopausal reference ranges. After 3 months' treatment the decrease in NTx and CTx was greater than that of Dpd (−50%, P < 0·0001 and −48%, P < 0·0001, compared with −11%, NS), as it was after 6 months (−51%, P < 0·0001, and −57%, P < 0·0001, compared with −19%, P < 0·01). The decrease in resorption markers after 6 months was significant in 23% (Dpd), 66% (NTx) and 66% (CTx) of individuals. Neither baseline resorption marker values nor the per cent change after 6 months' therapy correlated with bone mineral density change (BMD) at either lumbar spine or femoral neck after one year's therapy, except baseline Dpd and lumbar spine BMD (P < 0·01). We conclude that NTx and serum CTx were more sensitive markers of bone turnover suppression by alendronate, but only baseline Dpd was useful in the prediction of individual bone density response after one year.
CalvoMSEyreDRGrundbergCM. Molecular basis and clinical application of biological markers of bone turnover. Endocrine Rev1996; 17: 333–68.
2.
EriksenEFBrixenKCharlesP. New markers of bone metabolism: clinical use in metabolic bone disease: Review. Eur J Endocrinol1995; 132: 251–63.
3.
PriceCPThompsonPW. The role of biochemical tests in the screening and monitoring of osteoporosis. Ann Clin Biochem1995; 32: 244–60.
4.
BlumsohnAEastellR. The performance and utility of biochemical markers of bone turnover; do we know enough to use them in clinical practice?Ann Clin Biochem1997; 34: 449–59.
5.
KnottLBaileyAJ. Collagen cross-links in mineralizing tissues: a review of their chemistry, function and clinical relevance. Bone1998; 22: 181–7.
6.
EastellRColwellAHamptonLReeveJ. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis. J Bone Miner Res1997; 12: 59–65.
7.
JamesITWalneAJPerrettD. The measurement of pyridinium crosslinks: a methodological overview. Ann Clin Biochem1996; 33: 397–420.
8.
RobinsSPWoitgeHHesleyRJuJSeyedinSSeibelMJ. Direct, enzyme linked immunoassay for urinary deoxy pyridinoline is a specific marker for measuring bone resorption. J Bone Miner Res1994; 9: 1643–9.
9.
GertzBJShaoPHansonDAQuanHHarrisSTGenantHKMonitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res1994; 9: 135–42.
10.
BondeMQvistPFideliusCRiisBJChristiansenC. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem1994; 40: 2022–5.
11.
LibermanUAWeissSRBroilJMinneHWQuanHBellNHEffect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New Engl J Med1995; 333: 1437–43.
12.
RodanGAFleischHA. Bisphosphonates: Mechanisms of action. J Clin Invest1996; 97: 2692–6.
13.
AlakangasAESelanderKSHalleenJMönkkönenJVäanänenHK. Effect of alendronate on survival and activity of osteoclasts in vitro. Bone1997, 20(suppl 4): 113S.
14.
BondeMGarneroPFideliusCQvistPDelmasPDChristiansenC. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res1997; 12: 1028–34.
15.
FairneyAKydPThomasEWilsonJ. The use of cyclical etidronate in osteoporosis: changes after completion of 3 years' treatment. Br J Rheumatol1998; 37: 51–6.
16.
ChristgauSAlexandersenPSchlemmerABondeMQvistPChristiansenC. Biological variation in the serum concentration of degradation products derived from the C-terminal telopeptide of type I collagen measured by a new version of the Crosslaps™ ELISA. J Bone Miner Res1997; 12(suppl 1): S137.
StevensonHPLeslieHSheridanB. Intraindividual variation in serum type I procollagen carboxy-terminal propeptide and type I collagen carboxy-terminal cross-linked telopeptide concentrations. Ann Clin Biochem1997; 34: 317–8.
19.
BlumsohnANaylorKEAssiriAMAEastellR. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease. Clin Chem1995; 41: 1592–8.
20.
KushidaKTakahashiMKawanaKInoueT. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects and osteoporosis patients. J Clin Endocrinol Metab1995; 80: 2447–50.
21.
GarneroPShihWJGineytsEKarpfDBDelmasPD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab1994; 79: 1693–700.
22.
GarneroPHausherrEChapuyM-CMarcelliCGrandjeanHMullerCMarkers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res1996; 11: 1–8.
23.
PrestwoodKMPilbeamCCBurlesonJAWoodielFNDelmasPDDeftosLJThe short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab1994; 79: 366–71.
24.
GarneroPGineytsEArbaultPChristiansenCDelmasPD. Different effects of bisphosphonates and estrogen therapy on free and peptide bound bone cross-links excretion. J Bone Miner Res1995; 10: 641–9.
25.
KamelSFardellonePMeddahBLorget-GondelmannFSebertJLBrazierM. Response of several markers of bone collagen degradation to calcium supplementation in postmenopausal women with low calcium intake. Clin Chem1998; 44: 1437–42.
26.
JuH-S JLeungSBrownBStringerMALeighSScherrerCComparison of analytical performance and biological variability of three bone resorption assays. Clin Chem1997; 43: 1570–6.
27.
RobinsS. Collagen crosslinks in metabolic bone disease. Acta Orthop Scand1995; 66(Suppl 266): 171–5.
28.
HansonDAWeisMAEBollenAMMaslanSHSingerFREyreD. A specific immunoassay for monitoring human bone resorption: quantitation of type 1 collagen cross-linked N-telopeptides in urine. J Bone Miner Res1992; 7: 1251–58.
29.
ClemensJDHerrickMVSingerFREyreDR. Evidence that serum NTx (collagen type 1 N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem1997; 43: 2058–63.
30.
AponeSLeeMYEyreDR. Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone1997; 21: 129–36.
31.
BluhmsohnRAHannonRAAl-DehaimiAWEastellR. Short-term intraindividual variability of markers of bone turnover in healthy adults. J Bone Miner Res1994; 9(Suppl 1): S153.
32.
GreenspanSLDresner-PollakRParkerRALondonDFergusonL. Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tiss Int1997; 60: 419–23.
33.
ChristgauSBondeMQvistPChristiansenC. Measurement of serum Crosslaps™ concentration for rapid assessment of the anti-resorptive effect of alendronate treatment. J Bone Miner Res1997; 12(suppl 1): S137.
34.
RandallAGKentGNGarcia-WebbPBhagatCIPearceDJGutteridgeDHComparison of biochemical markers of bone turnover in Paget's disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links. J Bone Miner Res1996; 11: 1176–84.
35.
TobiasJHLaversuchCVWilsonNRobinsSP. Neridronate preferentially suppresses the urinary excretion of peptide-bound deoxypyridinoline in postmenopausal women. Calcif Tiss Int1996; 59: 407–9.
36.
GreenspanSLParkerRAKarpfDB. Short-term decreases in biochemical markers predict long-term response to alendronate therapy in representative elderly women. J Bone Miner Res1997; 12(Suppl 1): S170.
37.
BauerDCBlackDMOttSMSantoraAThompsonDEnnisMBiochemical markers predict spine but not hip BMD response to alendronate: the Fracture Intervention Trial (FIT). J Bone Miner Res1997; 12(Suppl 1): S150.
